 | | PRD_000186 | | Name: | EFRAPEPTIN C | | Formula: | C80 H138 N18 O16 | | Description: | EFRAPEPTIN C IS A LINEAR PEPTIDE, WITH ACETYLATED
(ACE) PIPECOLIC ACID (YCP) AT THE N-TERMINUS AND
A MODIFIED LEUCINE AT THE C-TERM (TLX) | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000951 | | Name: | 3-hydroxy-N-[(2S,3R)-3-hydroxy-4-{[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino}-1-phenylbutan-2-yl]benzamide | | Formula: | C28 H34 N2 O6 S | | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000187 | | Name: | SCYPTOLIN A | | Formula: | C45 H71 Cl N8 O14 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000952 | | Name: | N~2~-acetyl-N-[(2S,3R)-3-hydroxy-4-{[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino}-1-phenylbutan-2-yl]-L-isoleucinamide | | Formula: | C29 H43 N3 O6 S | | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000193 | | Name: | Capreomycin IA | | Formula: | C25 H44 N14 O8 | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000953 | | Name: | N-[(2S,3R)-4-{(cyclohexylmethyl)[(4-methoxyphenyl)sulfonyl]amino}-3-hydroxy-1-phenylbutan-2-yl]-3-hydroxybenzamide | | Formula: | C31 H38 N2 O6 S | | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000194 | | Name: | ACTAGARDINE | | Formula: | C81 H124 N20 O23 S4 | | Description: | ACTAGARDINE IS A TRICYCLIC PEPTIDE. POST TRANSLATIONAL MATURATION
OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR AND SER INTO
DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS WITH
CYSTEINE. THE THIOETHER BONDS WITH CYSTEINE RESULT IN THREE
RING STRUCTURES. THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND
CLEAVAGE OF THE MODIFIED PRECURSOR. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000954 | | Name: | 3-hydroxy-N-[(2S,3R)-3-hydroxy-4-{[(4-methoxyphenyl)sulfonyl](3-phenylpropyl)amino}-1-phenylbutan-2-yl]benzamide | | Formula: | C33 H36 N2 O6 S | | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000195 | | Name: | Cinnamycin | | Formula: | C89 H127 N25 O25 S3 | | Description: | CINNAMYCIN IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL MATURATION
OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR AND SER INTO
DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS WITH
CYSTEINE. THE 14-19 BETA-METHYLLANTHIONINE THIOETHER BOND IS OXIDIZED
TO A SULFOXIDE. THE THIOETHER BONDS WITH CYSTEINE RESULT IN THREE
RING STRUCTURES, CROSSLINK BETWEEN SER AND LYS RESULT IN THE FOURTH
RING. THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000955 | | Name: | 3-hydroxy-N-{(2S,3R)-3-hydroxy-4-[(2-methylpropyl){[5-(1,2-oxazol-5-yl)thiophen-2-yl]sulfonyl}amino]-1-phenylbutan-2-yl}benzamide | | Formula: | C28 H31 N3 O6 S2 | | Description: | SYNTHETIC HIV-1 PROTEASE INHIBITOR | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000196 | | Name: | EPILANCIN 15X | | Formula: | C145 H241 N41 O33 S3 | | Description: | Epilancin 15X is a tricyclic peptide. thioether bonds with cysteine
result in three rings along the peptide chain. Post Translational
maturation of lantibiotics involves the enzymic conversion of Thr and
Ser into dehydrated amino acids and the formation of thioether bonds
with cysteine. This is followed by membrane translocation and
cleavage of the modified precursor. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000197 | | Name: | ALPHA LICHENICIDIN PREPEPTIDE | | Formula: | C142 H226 N36 O41 S5 | | Description: | LICHENICIDIN VK21 IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL
MATURATION OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND
SER INTO DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS
WITH CYSTEINE. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR RINGS.
THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000198 | | Name: | BETA LICHENICIDIN PREPEPTIDE | | Formula: | C133 H200 N36 O37 S4 | | Description: | LICHENICIDIN VK21 IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL
MATURATION OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND
SER INTO DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS
WITH CYSTEINE. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR RINGS.
THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000959 | | Name: | 4-(benzyloxy)-N-[(2S,3R)-3-hydroxy-1-{[(2S)-1-{[(3-methylthiophen-2-yl)methyl]amino}-1-oxo-4-phenylbutan-2-yl]amino}-1-oxobutan-2-yl]benzamide | | Formula: | C34 H37 N3 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000199 | | Name: | Mersacidin | | Formula: | C80 H120 N20 O21 S4 | | Description: | MERSACIDIN IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL MATURATION
OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND SER INTO
DEHYDRATED AA AND THE FORMATION OF THIOETHER BONDS WITH CYSTEINE. THE
CARBOXY-TERMINAL BETA-METHYLLANTHIONINE UNDERGOES
DECARBOXYLATION. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR
RINGS. THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000200 | | Name: | Nisin A | | Formula: | C141 H233 N41 O38 S7 | | Description: | Nisin Z is a heptacyclic peptide. Post Translational maturation of
lantibiotics involves the enzymic conversion of Thr, and Ser into
dehydrated AA and the formation of thioether bonds with cysteine.
Thioether bonds with cysteine result in five cyclic structures along
the peptide chain. This is followed by membrane translocation and
cleavage of the modified precursor. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000964 | | Name: | N-(benzylsulfonyl)-D-alanyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide | | Formula: | C23 H29 Cl N4 O4 S | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000201 | | Name: | Alpha-Amanitin | | Formula: | C39 H54 N10 O14 S | | Description: | ALPHA-AMANITIN, IS AN 8 AMINO-ACID PEPTIDE.
THE OUTER LOOP IS FORMED BY A PEPTIDE BOND
BETWEEN THE C- AND THE N-TERMINI. THE SIDE-CHAINS
OF RESIDUES 2 AND 8 ARE LINKED TO FORM THE INNER
LOOP. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000966 | | Name: | [(5S)-5-[[(2S)-6-azaniumyl-2-[[(2S)-6-azaniumyl-2-[2-[[(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,20S)-20-[[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-azanyl-3-methyl-pentanoyl]amino]-3-oxidanyl-butanoyl]amino]-3-phenyl-propanoyl]amino]-2-(2-hydroxy-2-oxoethyl)-11,20-dimethyl-5,8-bis(2-methylpropyl)-3,6,9,21-tetrakis(oxidanylidene)-1,4,7,10-tetrazacyclohenicos-11-yl]carbonylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]ethanoylamino]hexanoyl]amino]hexanoyl]amino]-6-oxidanyl-6-oxidanylidene-hexyl]azanium | | Formula: | C87 H140 N17 O20 | | Definition date: | 2012-12-12 | | Last modified: | 2013-06-03 |
|
 | | PRD_000203 | | Name: | Chloroorienticin A | | Formula: | C73 H88 Cl2 N10 O26 | | Description: | CHLOROORIENTICIN A IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED BY ONE DISACCHARIDE ON RESIDUE 4 AND ONE MONOSACCHARIDE
ON RESIDUE 6. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000204 | | Name: | Vancomycin | | Formula: | C66 H75 Cl2 N9 O24 | | Description: | VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. | | Definition date: | 2012-12-12 | | Last modified: | 2022-01-06 |
|
 | | PRD_000205 | | Name: | DESVANCOSAMINYL VANCOMYCIN | | Formula: | C59 H62 Cl2 N8 O22 | | Description: | DESVANCOSAMINYL VANCOMYCIN IS AN INTERMIDIATE IN VANCOMYCIN BIOSYNTHESIS. IT IS TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED
BY D-GLUCOSE (RESIDUE 8) ON RESIDUE 4. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000971 | | Name: | N-acetylglycyl-N-[(3S)-1-hydroxy-5-methyl-2-oxohexan-3-yl]-L-serinamide | | Formula: | C14 H25 N3 O6 | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
 | | PRD_000206 | | Name: | VANCOMYCIN AGLYCON | | Formula: | C53 H52 Cl2 N8 O17 | | Description: | VANCOMYCIN AGLYCON IS THE NONSUGAR COMPONENT OF VANCOMYCIN, CONSISTING OF THE TRICYCLIC HEPTAPEPTIDE ONLY. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000972 | | Name: | N-(benzylsulfonyl)-D-valyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide | | Formula: | C25 H33 Cl N4 O4 S | | Definition date: | 2012-12-12 | | Last modified: | 2012-12-12 |
|
